- Home
- FGBI vs VIGL Comparison
FGBI vs VIGL Comparison
Compare FGBI & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGBI
- VIGL
- Stock Information
- Founded
- FGBI 1934
- VIGL 2020
- Country
- FGBI United States
- VIGL United States
- Employees
- FGBI N/A
- VIGL N/A
- Industry
- FGBI Savings Institutions
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- FGBI Finance
- VIGL Health Care
- Exchange
- FGBI Nasdaq
- VIGL Nasdaq
- Market Cap
- FGBI 107.7M
- VIGL 89.3M
- IPO Year
- FGBI N/A
- VIGL 2022
- Fundamental
- Price
- FGBI $9.84
- VIGL $1.71
- Analyst Decision
- FGBI
- VIGL Strong Buy
- Analyst Count
- FGBI 0
- VIGL 5
- Target Price
- FGBI N/A
- VIGL $16.33
- AVG Volume (30 Days)
- FGBI 14.6K
- VIGL 142.8K
- Earning Date
- FGBI 05-09-2025
- VIGL 05-06-2025
- Dividend Yield
- FGBI 2.64%
- VIGL N/A
- EPS Growth
- FGBI 31.17
- VIGL N/A
- EPS
- FGBI 0.81
- VIGL N/A
- Revenue
- FGBI $93,143,000.00
- VIGL N/A
- Revenue This Year
- FGBI $2.30
- VIGL N/A
- Revenue Next Year
- FGBI $2.98
- VIGL N/A
- P/E Ratio
- FGBI $12.16
- VIGL N/A
- Revenue Growth
- FGBI 1.72
- VIGL N/A
- 52 Week Low
- FGBI $6.56
- VIGL $1.31
- 52 Week High
- FGBI $15.25
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- FGBI 71.12
- VIGL 47.15
- Support Level
- FGBI $7.34
- VIGL $1.31
- Resistance Level
- FGBI $8.28
- VIGL $1.66
- Average True Range (ATR)
- FGBI 0.54
- VIGL 0.17
- MACD
- FGBI 0.29
- VIGL 0.03
- Stochastic Oscillator
- FGBI 97.17
- VIGL 71.33
About FGBI First Guaranty Bancshares Inc.
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.